Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Lowered by Cynosure Group LLC

Cynosure Group LLC decreased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,259 shares of the medical equipment provider’s stock after selling 1,287 shares during the period. Cynosure Group LLC’s holdings in Lantheus were worth $358,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after acquiring an additional 796,000 shares during the period. Swedbank AB bought a new position in Lantheus in the 1st quarter worth about $26,346,000. Point72 Asset Management L.P. acquired a new stake in shares of Lantheus in the second quarter valued at approximately $26,794,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the third quarter valued at approximately $25,955,000. Finally, LSV Asset Management raised its holdings in shares of Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after buying an additional 139,647 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $90.27 on Friday. The stock has a market capitalization of $6.28 billion, a price-to-earnings ratio of 15.02 and a beta of 0.51. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a 50 day moving average price of $102.12 and a 200 day moving average price of $97.09.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Truist Financial reissued a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities lowered their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.